MedTrace Logo

Study of Colorectal Cancer Screening Options

NCT05987709 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2004

Last updated 2025-12-16

Study results available
· View outcomes & findings →

Summary

The investigators propose to evaluate Guardant Health's commercially available colorectal cancer screening assay(Guardant SHIELD) in individuals who are not up to date with CRC screening.

Conditions

Interventions

DIAGNOSTIC_TEST

GuardantSHIELD Blood Test

The GuardantSHIELD CRC screening test is a commercially available test which works by finding signs of colorectal tumor in the blood of patients at average risk for CRC

Sponsors & Collaborators

  • Kaiser Permanente

    lead OTHER

Principal Investigators

  • Gloria Coronado, PhD · Kaiser Permanente

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-17
Primary Completion
2022-12-31
Completion
2023-06-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05987709 on ClinicalTrials.gov